Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells $200,833.44 in Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 664 shares of the company’s stock in a transaction dated Wednesday, July 8th. The shares were sold at an average price of $302.46, for a total transaction of $200,833.44. Following the completion of the sale, the senior vice president owned 202 shares in the company, valued at approximately $61,096.92. This trade represents a 76.67% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Chan Henry Lee also recently made the following trade(s):

• On Tuesday, June 16th, Chan Henry Lee sold 590 shares of BeOne Medicines stock. The shares were sold at an average price of $265.98, for a total value of $156,928.20.
• On Thursday, June 11th, Chan Henry Lee sold 428 shares of BeOne Medicines stock. The shares were sold at an average price of $257.63, for a total value of $110,265.64.
• On Monday, June 8th, Chan Henry Lee sold 871 shares of BeOne Medicines stock. The shares were sold at an average price of $270.42, for a total value of $235,535.82.
• On Wednesday, May 13th, Chan Henry Lee sold 332 shares of BeOne Medicines stock. The stock was sold at an average price of $310.72, for a total value of $103,159.04.

BeOne Medicines Price Performance

Shares of ONC opened at $298.70 on Monday. The firm has a market cap of $32.77 billion, a price-to-earnings ratio of 66.82 and a beta of 0.49. The stock has a 50 day moving average of $289.89 and a 200-day moving average of $309.00. The company has a current ratio of 3.64, a quick ratio of 3.27 and a debt-to-equity ratio of 0.20. BeOne Medicines Ltd. – Sponsored ADR has a 52 week low of $249.00 and a 52 week high of $385.22.

BeOne Medicines (NASDAQ:ONC) last posted its quarterly earnings results on Wednesday, April 1st. The company reported $0.25 earnings per share (EPS) for the quarter. BeOne Medicines had a return on equity of 12.06% and a net margin of 8.94%.The business had revenue of $1.51 billion for the quarter. As a group, analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 5.86 EPS for the current year.

Institutional Investors Weigh In On BeOne Medicines

A number of hedge funds have recently added to or reduced their stakes in the stock. Capital International Investors boosted its holdings in shares of BeOne Medicines by 1.3% during the fourth quarter. Capital International Investors now owns 5,113,866 shares of the company’s stock valued at $1,553,909,000 after acquiring an additional 67,808 shares during the period. Siren L.L.C. increased its holdings in shares of BeOne Medicines by 1.4% in the 4th quarter. Siren L.L.C. now owns 500,000 shares of the company’s stock worth $151,905,000 after acquiring an additional 7,010 shares during the period. Morgan Stanley lifted its position in BeOne Medicines by 23.9% in the 4th quarter. Morgan Stanley now owns 437,661 shares of the company’s stock valued at $132,966,000 after purchasing an additional 84,367 shares during the last quarter. Bank of America Corp DE lifted its position in BeOne Medicines by 7.0% in the 1st quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after purchasing an additional 26,441 shares during the last quarter. Finally, Candriam S.C.A. boosted its stake in BeOne Medicines by 31.7% during the 1st quarter. Candriam S.C.A. now owns 259,731 shares of the company’s stock valued at $77,132,000 after purchasing an additional 62,470 shares during the period. 48.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on ONC. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Monday, April 20th. Barclays boosted their price objective on shares of BeOne Medicines from $405.00 to $409.00 and gave the company an “overweight” rating in a research report on Thursday, May 7th. Wolfe Research started coverage on shares of BeOne Medicines in a research note on Friday, March 27th. They set an “outperform” rating and a $340.00 price objective on the stock. Wells Fargo & Company started coverage on shares of BeOne Medicines in a report on Monday, May 4th. They issued an “overweight” rating and a $400.00 target price on the stock. Finally, Leerink Partners lifted their target price on BeOne Medicines from $364.00 to $367.00 and gave the company an “outperform” rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $391.38.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.